跳至主要内容
临床试验/CTRI/2018/03/012697
CTRI/2018/03/012697已完成2 期

Clinical Evaluation for the Thrombopoietic Activity of Platenza Tablet in Cases of Dengue with Thrombocytopenia- Randomized Open Label Comparative Clinical Study

The Himalaya Drug Company Ltd0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Both male and female subjects between the age group of >=18 years to <= 60years who are confirmed to have DF (Dengue Fever) grade 1 and grade 2 by IgG, IgM and NS1 Antigen.
  • 2.Subjects who have been diagnosed with clinically significant dengue fever associated with thrombocytopenia with platelet count between 30000/µL to 1,00,000/µL.
  • 3.Subjects with the SGPT level not more than 2 times the upper limit of normal.
  • 4.Subjects with stable vitals like pulse and blood pressure
  • 5.Subjects willing to give written informed consent
  • 6.Subjects who had not participated in similar kind of study in last 3 months were included into the study.

排除标准

  • 1 Subject diagnosed with DHF Grade 3 or 4.
  • 2 Subjects platelet count <30000/µL.
  • 3 Subject presenting with hemorrhagic phenomena at screening evidenced with positive Torniquette test, petechiae, ecchymoses, or purpura, bleeding from the mucosa, gastrointestinal tract, injection sites or other locations and haemetemesis or melaena are excluded from the study.
  • 4 Bleeding disorders or those taking blood thinning medications such as aspirin or warfarin.
  • 5 Subjects with the history of diabetes mellitus treated with any Oral Hypoglycaemic Agents.
  • 6 Subjects with the history of clinically significant cardiovascular condition treated with the medication Amiodarone
  • 7 Subjects with infectious condition treated with antibiotics like penicillin G , ampicillin, amoxyclav, cephalothin,polymyxin B, rifampicin, amikacin, nalidixic acid, gentamycin, cholarmphenicol, oflxacin.
  • 8 Subjects with established hematological disorders including idiopathic thrombocytopenia purpura, leukemia, hemophilia.
  • 9 Has received blood products or blood transfusion during the current hospital stay Or during last one month
  • 10 Hypersensitive to any of the ingredients.
  • 11 Use of prescription medication to treat gastric problems
  • 12 Pregnant & lactating women.
  • 13 Subjects not willing to sign informed consent form.

研究者

相似试验

Tablets for dengue | 临床试验